Replies to post #12863 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

Revenue for imatinib in CML was estimated to be more than $3 billion in 2010.

[DonShimoda]

I'll have to go back and check to be sure, but, I believe Sprycel's MCyr was in the low 60% and Tasigna upper 50% (not sure if this was 12 or 24 months). Considering Ponatinib achieved 72% in what is arguably a more heavily pre-treated patient population is certainly impressive.